Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma

Prof. Toni Choueiri

The multinational phase 3 study CheckMate 9ER compared the combination of nivolumab plus cabozantinib versus sunitinib for previously untreated advanced renal-cell carcinoma. Patients in the combination group had significantly better progression-free survival, overall survival, and likelihood of response.